Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine
On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartï¾’s recombinant…
COVID-19 immunity may last six months or more
On Nov. 11, 2020, Howard Hughes Medical Institute Investigator Michel Nussenzweig and his team reported that people who…
EUROIMMUN launched quantitative ELISA to measure SARS-CoV-2 antibodies against viral S1 protein
On Nov. 9, 2020, PerkinElmer announced that EUROIMMUN, a PerkinElmer company, had launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG)…
FDA authorized first test that detected neutralizing antibodies from recent or prior SARS-CoV-2 infection
On Nov. 6, 2020, the FDA authorized the first serology test that detected neutralizing antibodies from recent or…
InBios awarded $12.7M to boost production of two COVID-19 diagnostics
On Oct. 31, 2020, the U.S. Department of Health and Human Services and the U.S. Department of Defense…
UNMC VA study found contaminants may increase risk of rheumatoid arthritis
On Oct. 28, 2020, researchers at the University of Nebraska Medical Center (UNMC) reported the results of a…
Antibodies co-invented by Scripps Research and IAVI developed as a potential COVID-19 therapy
On Aug. 27, 2020, immunologists at Scripps Research, in partnership with colleagues at the IAVI Neutralizing Antibody Center,…
IAVI, Merck, and Serum Institute joined forces to develop monoclonal antibodies for COVID-19
On Oct. 22, 2020, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges,…
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
Bio-Techne announced commercial release of SARS-CoV-2 multi-antigen serology assay kit for simple western
On Oct. 19, 2020, Bio-Techne announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for…
LabCorp launched quantitative antibody test to assess effectiveness ef COVID-19 vaccines in clinical trials
On Oct. 19, 2020, LabCorp announced a test that provided a quantitative measurement of an individualï¾’s SARS-CoV-2 IgG…
Just – Evotec Biologics received grant to enable an antibody product for the prevention of COVID-19
On Oct. 19, 2020, Evotec announced that its Seattle-based subsidiary, Just – Evotec Biologics had received a grant…
FDA authorized phase 1 trial of ImmunityBioï¾’s novel COVID-19 vaccine candidate hAd5 to drive T cell and antibody immunity
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
FDA approved first treatment for Ebola virus
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
US DOD expanded collaboration with AstraZeneca to develop and manufacture an investigational mab to prevent COVID-19
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
Emergent BioSolutionsï¾’ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
Sorrento announced discovery of salicyn-30 small molecule that strongly inhibits SARS-CoV-2 infection
On Oct. 7, 2020, Sorrento Therapeutics announced that it had discovered a small molecule termed Salicyn-30 that demonstrated…
Lilly updated progress of SARS-CoV-2 neutralizing antibody programs
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ï¾– including interim…
Sorrento Therapeutics and ViralClear entered agreement to explore combination antibody plus antiviral therapy against COVID-19
On Sept. 30, 2020, ViralClear Pharmaceuticals and Sorrento Therapeutics announced the companies were exploring the synergistic potential of…
FDA authorized first point-of-care antibody test for COVID-19
On Sept. 23, 2020, the FDA issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care…
Oxford Immunotec joined with Public Health England in large clinical trial utilizing T-SPOT discovery SARS-CoV-2 test
On Sept. 22, 2020, Oxford Immunotec announced that it had entered into an extensive research collaboration with Public…
XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVIDï¾™ for…
Roche launched new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines
On Sept. 18, 2020, Roche announced the launch of its Elecsysï¾® Anti-SARS-CoV-2 S antibody test for markets accepting…
Lilly and Amgen announced manufacturing collaboration for COVID-19 antibody therapies
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the…
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…